JPMorgan Reinstates BeOne Medicines (ONC) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ONC Hot Sheet
Price: $361.27 -2.45%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on BeOne Medicines (NASDAQ: ONC) with a Overweight rating and a price target of $415.00.
For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.
Shares of BeOne Medicines closed at $297.01 yesterday.
You May Also Be Interested In
- Wedbush Starts Nuscale Power (SMR) at Underperform
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- H.C. Wainwright Assumes Autolus Therapeutics plc (AUTL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
